Literature DB >> 27379542

Altered matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 levels in children with primary hypertension.

Anna Niemirska1, Mieczysław Litwin, Joanna Trojanek, Lidia Gackowska, Izabela Kubiszewska, Aldona Wierzbicka, Zbigniew Kułaga, Jacek Michałkiewicz.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) are involved in cardiovascular remodeling in hypertension. Because metabolic abnormalities typical of metabolic syndrome is the dominant phenotype of primary hypertension in children, we hypothesized that MMP-9 and TIMP-1 plasma concentrations are altered in hypertensive children and correlate with metabolic abnormalities and target organ damage.
METHOD: A total of 109 children (15.6, 10-17 years) with untreated primary hypertension were included to the study. The control group consisted of 74 healthy, normotensive children.
RESULTS: Plasma MMP-9, TIMP-1 concentrations, and MMP-9/TIMP-1 ratio were significantly elevated in hypertensive boys in comparison with normotensive boys (P = 0.0001, P = 0.04, and P = 0.001, respectively), whereas there were no differences between hypertensive and normotensive girls. The levels of MMP-9 and TIMP-1 as well as MMP-9/TIMP-1 ratio were not associated either with hypertension stage, left ventricular hypertrophy, or carotid intima-media thickness. However, in a subgroup of 30 hypertensive patients in whom arterial stiffness was measured, TIMP-1 concentrations correlated with aortic pulse pressure (P < 0.05; r = 0.367), augmentation pressure (P < 0.05; r = 0.428), and augmentation index (P < 0.05; r = 0.404).Only hypertensive boys presented negative correlations of both MMP-9 and TIMP-1 levels with high-density lipoprotein cholesterol (r = -0.254, P = 0.01 and r = -0.241, P = 0.02, respectively).
CONCLUSION: Hypertensive boys but not girls had elevated MMP-9 and TIMP-1 plasma concentrations, which indicates sex-related role of MMP/TIMP system in pediatric hypertension. The correlation between serum TIMP-1 and markers of arterial stiffness indicates on the involvement of TIMPs in arterial remodeling.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27379542     DOI: 10.1097/HJH.0000000000001024

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  4 in total

1.  Comparison of the perioperative time courses of matrix metalloproteinase-9 (MMP-9) and its inhibitor (TIMP-1) during carotid artery stenting (CAS) and carotid endarterectomy (CEA).

Authors:  Ákos Mérei; Bálint Nagy; Gábor Woth; János Lantos; Ferenc Kövér; Lajos Bogár; Diána Mühl
Journal:  BMC Neurol       Date:  2018-08-29       Impact factor: 2.474

2.  Matrix metalloproteinase -2, -9 and arterial stiffness in children and adolescents: The role of chronic kidney disease, diabetes, and hypertension.

Authors:  Stella Stabouli; Vasilios Kotsis; Olga Maliachova; Nikoleta Printza; Athanasia Chainoglou; Athanasios Christoforidis; Anna Taparkou; John Dotis; Evangelia Farmaki; Dimitrios Zafeiriou
Journal:  Int J Cardiol Hypertens       Date:  2020-02-06

3.  Obesity, metabolic syndrome, and primary hypertension.

Authors:  Mieczysław Litwin; Zbigniew Kułaga
Journal:  Pediatr Nephrol       Date:  2020-05-09       Impact factor: 3.714

4.  Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Peripheral Blood Leukocytes and Plasma of Children with Nonalcoholic Fatty Liver Disease.

Authors:  Joanna B Trojanek; Jacek Michałkiewicz; Renata Grzywa-Czuba; Wojciech Jańczyk; Lidia Gackowska; Izabela Kubiszewska; Anna Helmin-Basa; Aldona Wierzbicka-Rucińska; Mieczysław Szalecki; Piotr Socha
Journal:  Mediators Inflamm       Date:  2020-09-10       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.